Resveratrol has been reported to be beneficial against diabetes complications. The objective\nof this study was to evaluate the efficacy of resveratrol in decreasing hyperglycemia in patients with\ntype 1 diabetes (T1D) by a preliminary investigation designed as an exploratory clinical trial. Thirteen\npatients with T1D from both the sexes participated in this trial. All patients received resveratrol in 500\nmg capsules, twice daily for 60 days. Bodyweight, fasting blood sugar (FBS), hemoglobin A1c (HbA1c),\ninsulin, homeostasis model of assessment for insulin resistance (HOMA-IR), homeostasis model of\nassessment for Beta-cell function (HOMA-Beta), and markers of liver and kidney damage, inflammation,\nand oxidative stress were measured before the intervention, at 30 days and at 60 days. Resveratrol\nsupplementation for 60 days significantly decreased FBS and HbA1c in comparison with the baseline\nvalues. Resveratrol treatment also resulted in a decrease in the level of a marker for oxidative stress,\nmalondialdehyde, and an increase in total antioxidant capacity in T1D patients. Insulin, HOMA-IR,\nHOMA-Beta, and markers of liver and kidney function and inflammation were not significantly affected\nby resveratrol treatment. Overall, the results showed that 60 days of resveratrol supplementation\nexerted strong antidiabetic and antioxidant effects in patients with T1D.
Loading....